KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $523.4 million.

  • Vertex Pharmaceuticals' Other Operating Expenses rose 268.79% to $523.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year decrease of 6483.83%. This contributed to the annual value of $2.2 billion for FY2025, which is 6483.83% down from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Other Operating Expenses is $523.4 million, which was up 268.79% from $467.4 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' Other Operating Expenses' 5-year high stood at $4.8 billion during Q2 2024, with a 5-year trough of $188.4 million in Q1 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $409.2 million (2024), whereas its average is $660.6 million.
  • In the last 5 years, Vertex Pharmaceuticals' Other Operating Expenses skyrocketed by 105209.08% in 2024 and then plummeted by 9148.4% in 2025.
  • Vertex Pharmaceuticals' Other Operating Expenses (Quarter) stood at $371.9 million in 2021, then decreased by 17.26% to $307.7 million in 2022, then rose by 9.03% to $335.5 million in 2023, then surged by 51.92% to $509.7 million in 2024, then rose by 2.69% to $523.4 million in 2025.
  • Its Other Operating Expenses was $523.4 million in Q4 2025, compared to $467.4 million in Q3 2025 and $410.6 million in Q2 2025.